NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Medical Technologies Advisory Committee (MTAC) meeting minutes

**Minutes:** Confirmed

**Date and time: 104th MTAC meeting - Friday 23rd July 2021**

**Location:** via Zoom

## Attendees

Committee members present

1. Shaheen Hamdy (Interim Vice Chair) Present for all items
2. Donna Cowan Present for items 1-5.2
3. Julian Dunnett Present for all items
4. Jeremy Henning Present for all items
5. Mohammad Ilyas Present for all items
6. Michael Kolovetsios Present for items 1-4.1

 & 5-7

1. Emily Lam Present for all items
2. Avril McCarthy Present for items 5-7
3. Karen McCutcheon Present for items 5-7
4. Duncan McPherson Present for all items
5. Naomi McVey Present for all items
6. Huseyin Naci Present for all items
7. Abdullah Pandor Present for all items
8. Jai Patel Present for all items
9. Allan Wailoo Present for items 1-6.2
10. Alun Williams Present for items 1-4.2

NICE staff present

Anastasia Chalkidou, Associate Director Present for all items

Victoria Fitton, Project Manager Present for all items

Izabela Syrek, Administrator Present for all items

Chris Pomfrett, Technical Adviser – Research Commissioning Present for all items

Lizzy Latimer, Health Technology Assessment Adviser Present for items 5-5.2

Kimberley Carter, Health Technology Assessment Adviser Present for items 1-4.2 & 6-7

Ying-Ying Wang, Health Technology Assessment Analyst Present for items 1-4.2

Charlotte Pelekanou, Health Technology Assessment Analyst Present for items 1-5.2

Lirije Hyseni, Health Technology Assessment Analyst Present for items 6-6.2

Samantha Baskerville, Health Technology Assessment Analyst Present for items 1-5.2

Dionne Bowie, Health Technology Assessment Analyst Present for all items

Federica Ciamponi, Health Technology Assessment Analyst Present for items 1-5.2

Alexa Forrester, Health Technology Adoption Manager, Adoption & Impact team Present for all items

Rosalee Mason, Corporate Office Coordinator Present for all items 1-

 4.1; 5 – 5.1 & 6-6.1

Lucinda Evans, Corporate Office Coordinator Present for items 5-5.1

Ian Mather, Business Analyst Present for all items

Dr Mark Kroese, Director / Consultant in Public Health Medicine, PHG Foundation Present for all items

Sarah Kotecha, Assistant Systematic Reviewer, Cardiff University working with Cedar EAC Present for all items

EAC representatives present

Dr Susan O'Connell, Senior Researcher, Cedar Present for items 1-4.1 & 6-6.1

Dr Michal Pruski, Healthcare Scientist (Evaluation), Cedar Present for items 1-4.1

Dr Jamie Erskine, Health Technology Assessor, KiTEC Present for items 5- 5.1

Dr Murali Kartha, Health Economist, KiTEC Present for items 5- 5.1

Dr Megan Dale, Senior Researcher, Cedar Present for items 6-6.1

Professional experts present

Dr Stephen Playfor, Consultant Paediatric Intensivist, Manchester University NHS Foundation Trust Present for items 1- 4.1

Prof Anil Hormis, Consultant in Anaesthesia & Critical Care Medicine, The Rotherham NHS Foundation Trust Present for items 1- 4.1

Dr Mark Devonald, Consultant Nephrologist, Liverpool University Hospital NHS Foundation Trust Present for items 5- 5.1

Prof Azfar Zaman, Consultant Cardiologist, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust Present for items 5- 5.1

Dr Yahya Al Najjar, Consultant Interventional Cardiologist, Manchester University NHS Foundation Trust Present for items 5- 5.1

Dr Daniel Conroy, Interventional Radiologist, Belfast Health and Social Care Trust

 Present for items 5- 5.1

Dr Sudhir Rathore, Consultant Cardiologist, NHS Frimley Health Foundation Trust Present for items 5- 5.1

Mr Mark Collier, Nurse Consultant and Associate Lecturer - Tissue Viability (UK) & Chair of the Leg Ulcer Forum (England and Wales) Present for items 6-6.1

Ms Denise Woodd, Independent Clinical Nurse Specialist, NHS Portsmouth CCG / Solent NHS Trust Present for items 6-6.1

## 1. Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Fiona Denison (Vice-chair), Teik Goh, Stephen Habgood, Cynthia Iglesias, David Partridge and Carl Roobottom.

## 2. News and announcements

* 1. none

## 3. Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on 18 June 2021

## 4. Evaluation of AnaConDa-S for sedation with volatile anaesthetics in intensive care

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Sedana Medical and Miller Economics Ltd.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Dr Jeremy Henning declared a non-financial professional interest as he was supplied 3 units, by the then UK supplier (it was a very different supplier), to take to Iraq during the second gulf war in 2001, to conduct field trials to evaluate whether or not the British Army were interested in them. The units malfunctioned in the heat, so they did not buy them, and Jeremy did publish a letter in Anaesthesia about it.

It was agreed that his declaration would not prevent Dr Henning from participating in this section of the meeting.

* Mr Michael Kolovetsios declared an indirect financial interest as Medtronic (his employer) manufactures intubation products and Anaconda covers Medtronic’s respiratory portfolio. Anaconda can be classed as a competitor product as it can be used in place of Medtronic’s ventilator filters.

It was agreed that his declaration would prevent Mr Kolovetsios from participating in the closed committee discussion and he had to leave the meeting for part 2.

* Dr Stephen Playfor declared a non-financial professional interest as he has been asked by Sedana Medical to participate in an online workshop at some point later in 2020 to discuss his experience of using the AnaConDa system. He is not anticipating being offered any sort of fee to speak, but it might be considered to enhance his professional standing.

It was agreed that his declaration would not prevent Dr Playfor from providing expert advice to the committee.

* Prof Anil Hormis declared a direct financial interest as he has received honoraria from Teleflex for lectures / teaching (No conflict declared). Ha also received honoraria from Medtronic for lectures / teaching (No conflict declared).

It was agreed that his declaration would not prevent Prof Hormis from providing expert advice to the committee.

* + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Mr Alun Wiliams and Dr Huseyin Naci.
	1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Medical Technology Consultation Document (MTCD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Medical Technology Consultation Document (MTCD) in line with their decisions.

## 5. Evaluation of DyeVert for reducing contrast media in coronary and peripheral angiography

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Osprey Medical.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Mark Devonald declared a non-financial professional interest as he is co-inventor on a patent (owned by Nottingham University Hospitals and University of Nottingham) for urinary biomarkers for the early detection of acute kidney injury.

It was agreed that his declaration would not prevent Dr Devonald from providing expert advice to the committee.

* Prof Azfar Zaman declared a non-financial professional interest as he is a co-author on scientific paper.

It was agreed that his declaration would not prevent Prof Zaman from providing expert advice to the committee.

* Dr Yahya Al Najjar declared a non-financial professional interest as he is a co-author on scientific paper.

It was agreed that his declaration would not prevent Dr Najjar from providing expert advice to the committee.

* + 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Mr Jeremy Henning and Dr Julian Dunnett.
	1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Medical Technology Guidance (MTG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Medical Technology Guidance (MTG) in line with their decisions.

## 6. Evaluation of Prontosan for acute and chronic wounds

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from B. Braun Medical Ltd.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Mr Mark Collier declared a non-financial professional interest as he has attended and participated in various meetings – National and International - discussing the clinical benefits and potential further development of the use of the product.

It was agreed that his declaration would not prevent Mr Collier from providing expert advice to the committee.

* Ms Denise Woodd declared a direct financial interest as she supported part time post to advise and educate primary care nursing staff (honorary contract currently with both Trusts who endorsed the supported post). She sometimes do teaching or support work for her local Trust with an honorary contract and BBraun support those hours.

It was agreed that her declaration would not prevent Ms Woodd from providing expert advice to the committee.

* + 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Dr Karen McCutcheon and Prof Allan Wailoo.
	1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Medical Technology Guidance (MTG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Medical Technology Guidance (MTG) in line with their decisions.

## 7. Date of the next meeting

The next meeting of the Medical Technologies Advisory Committee (MTAC) will be held on 20 August 2021 and will start promptly at 9:00am.